Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dual specificity phosphatase 28 (DUSP28)
- Target
- DUSP28
- Molecular classification
- Enzyme, Protein tyrosine phosphatase, Dual-specificity phosphatase, Atypical DUSP subfamily
01
Overview
Dual specificity phosphatase 28 is an enzyme belonging to the atypical DUSP subfamily. It catalyzes the removal of phosphate groups from tyrosine and threonine residues of protein substrates, but has atypically low intrinsic catalytic activity due to steric hindrance in its active site. DUSP28 is implicated in cell signaling regulation, particularly as a modulator of the MAPK/ERK pathway, and is associated with the progression, migration, and drug resistance of pancreatic and hepatocellular carcinomas. It is being investigated as a potential biomarker and therapeutic target in oncology
- Other names
- DUSP28VH1-like phosphatase (VHP)
02
Mechanism of action
Drugs targeting DUSP28 would theoretically act by inhibiting its phosphatase activity, thereby sensitizing cancer cells to apoptosis via reactivation of MAPK/ERK1/2 or other stress-responsive pathways
03
Biological functions
Dephosphorylation (removal of phosphate groups from proteins)Regulation of MAPK signaling pathways, including ERK1/2 and possibly p38Cell migrationApoptosisCell cycle regulationDrug resistance in cancer cells
04
Disease associations
Cancer (especially pancreatic and hepatocellular carcinoma)ChemoresistanceCell migration contributing to metastasis
05
Safety considerations
Specific safety concerns for targeting DUSP28 are not described in the available literature; potential challenges may include off-target effects due to similarity with other DUSPs and the physiological role of DUSP28 in normal tissue
06
Biomarkers
High DUSP28 expression in tumor tissue (especially in pancreatic and liver cancers) is associated with poor prognosis and chemoresistance; DUSP28 expression could be evaluated as a biomarker for drug sensitivity or metastatic potential
Beyond the preview
Go deeper on Dual specificity phosphatase 28 (DUSP28).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dual specificity phosphatase 28 (DUSP28).